|Publication type:||Article in scientific journal|
|Type of review:||Peer review (publication)|
|Title:||Challenges with matrix metalloproteinase inhibition and future drug discovery avenues|
|Published in:||Expert Opinion on Drug Discovery|
|Publisher / Ed. Institution:||Taylor & Francis|
|Subjects:||Antibodies; Drug design; Drug discovery; Hemopexin-like domain; Matrix metalloproteinase; Medicinal chemistry; Polypharmacology; Small-molecule inhibitors|
|Subject (DDC):||615: Pharmacology and therapeutics|
|Abstract:||Matrix metalloproteinases have been in the scope of pharmaceutical drug discovery for decades as promising targets for drug development. Until present, no modulator of the enzyme class survived clinical trials, all failing for various reasons. Nevertheless, the target family did not lose its attractiveness and there is ever more evidence that MMP modulators are likely to overcome the hurdles and result in successful clinical therapies.|
|Fulltext version:||Published version|
|License (according to publishing contract):||Licence according to publishing contract|
|Departement:||Life Sciences and Facility Management|
|Organisational Unit:||Institute of Chemistry and Biotechnology (ICBT)|
|Appears in collections:||Publikationen Life Sciences und Facility Management|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.